GreenLight Biosciences Holdings
GRNAW
NASDAQ Global Market0.02
USD
+0.00
- -
CIK
0001822691
CUSIP
39536G113
Return %
Stock
S&P500
1Y
-95.22
18.99
3Y
-98.05
64.75
5Y
-98.05
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 280
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Boston Avenue Medford MA United States of America 02155
- CIK
- 0001822691
- Website
- greenlightbiosciences.com
- Similar Companies
- Business
- GreenLight Biosciences Holdings, founded in 2008 and headquartered in Medford, Massachusetts, operates as a bio-production platform specializing in RNA technology for agriculture, human health, and ingredient sectors. The company develops and manufactures RNA-based solutions including insecticides, fungicides, herbicides, and honeybee protection products aimed at sustainable food production and environmental preservation. Its agricultural product pipeline addresses critical crop protection needs such as pest and disease management across fruits, vegetables, and large-scale crops, with notable products in regulatory review including a groundbreaking RNA-based treatment for grape powdery mildew and Norroa™, the first nature-based RNAi solution to protect honeybees from varroa mites. GreenLight also focuses on human health through preclinical messenger RNA vaccine and therapeutic development, including a universal pan-sarbecovirus vaccine and personalized oncology treatments. Recent major company developments include GreenLight’s successful completion of a $45.5 million all-cash go-private acquisition by a consortium led by Fall Line Capital in 2023, accompanied by a significant secured convertible note financing of up to $100 million. The company has expanded its agricultural business into Mexico, broadening its market reach. It acquired rights to portions of Bayer’s topical RNA intellectual property portfolio to enhance its RNA-based product offerings. Additionally, GreenLight submitted regulatory dossiers in the US, EU, and Brazil for key RNA-based crop protection products and achieved EPA registration of Norroa™, marking a milestone in sustainable agricultural solutions. The company continues to advance RNA herbicide development for more sustainable weed control, further diversifying its product portfolio. GreenLight Biosciences maintains a patent-protected RNA platform and remains committed to leveraging RNA technology for innovative solutions in human and plant health across global markets including North America, Latin America, and Europe. These initiatives underscore its strategic shift toward growing its RNA-based agricultural pipeline alongside its human health research programs.